Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Perjeta, Avastin Breast Cancer Approvals Are A Study In Contrasts

Jun 25 2012

• By Sue Sutter

Related Content

Avastin Down, But Not Out Yet In Metastatic Breast Cancer Indication

Dec 20 2010

Genentech Restricts Population In Last-Ditch Bid To Keep Avastin's Breast Cancer Claim

Aug 05 2011

Avastin’s Breast Cancer Approval Followed CDER Rift On Efficacy

May 30 2011

Genentech Thinks Pertuzumab Will Escape <em>Avastin</em> Problem, Despite Similarities

Dec 12 2011

Genentech’s <em>Perjeta</em> Clears FDA Despite Unresolved Manufacturing Issues

Jun 18 2012

Avastin Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions

Nov 21 2011

<i>Avastin</i>’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?

Jul 04 2011

<i>Avastin</i> Debate Could Provide Clarity On Use Of Progression-Free Survival Endpoints

Jul 11 2011

Related Companies

Genentech, Inc.

Agilent Technologies, Inc.

Additional Topics

United States Clinical Trials BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window